FDA Grants XTANDI application Priority Review for metastatic hormone-sensitive prostate cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

FDA has accepted for review the filing of a supplemental New Drug Application for XTANDI (enzalutamide) to add an indication for the treatment of men with metastatic hormone-sensitive prostate cancer.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Confidential Trump administration budget documents show that the upcoming FY26 Budget Request will radically cut about $50 billion out of the U.S. Department of Health and Human Services, reshuffling agency components, and slashing the number of NIH institutes and centers to just eight. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login